This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wire, M. B.
Right arrow Articles by Berrey, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wire, M. B.
Right arrow Articles by Berrey, M. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1578-1580, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1578-1580.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

Mary B. Wire,1* Katherine L. Baker,1 Lori S. Jones,1 Mark J. Shelton,1 Yu Lou,2 Greg J. Thomas,3 and M. Michelle Berrey1

Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina,1 Clinical Pharmacology Data Science, GlaxoSmithKline, Research Triangle Park, North Carolina,2 Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Philadelphia, Pennsylvania3

Received 15 September 2005/ Returned for modification 30 October 2005/ Accepted 16 January 2006

To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir.

* Corresponding author. Mailing address: Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, 5 Moore Dr., 17.2231.2B, Research Triangle Park, NC 27709. Phone: (919) 483-5852. Fax: (919) 483-6380. E-mail: Mary.B.Wire{at}gsk.com.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1578-1580, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1578-1580.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Perez-Elias, M. J., Morellon, M. L., Ortega, E., Hernandez-Quero, J., Rodriguez-Torres, M., Clotet, B., Felizarta, F., Gutierrez, F., Pineda, J. A., Nichols, G., Lou, Y., Wire, M. B. (2009). Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. Antimicrob. Agents Chemother. 53: 5185-5196 [Abstract] [Full Text]  
  • Ford, S. L., Chen, Y.-C., Lou, Y., Borland, J., Min, S. S., Yuen, G. J., Shelton, M. J. (2008). Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Antimicrob. Agents Chemother. 52: 534-538 [Abstract] [Full Text]  
  • Okusanya, O., Forrest, A., DiFrancesco, R., Bilic, S., Rosenkranz, S., Para, M. F., Adams, E., Yarasheski, K. E., Reichman, R. C., Morse, G. D., and the ACTG 5043 Protocol Team, (2007). Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrob. Agents Chemother. 51: 1822-1826 [Abstract] [Full Text]  
  • Pellegrin, I., Breilh, D., Coureau, G., Boucher, S., Neau, D., Merel, P., Lacoste, D., Fleury, H., Saux, M.-C., Pellegrin, J.-L., Lazaro, E., Dabis, F., Thiebaut, R., for the ANRS Co3 Aquitaine Cohort, (2007). Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrob. Agents Chemother. 51: 1473-1480 [Abstract] [Full Text]  
  • DeJesus, E., Piliero, P. J., Summers, K., Wire, M. B., Stein, D. S., Masterman, A., Lou, Y., Min, S. S., Shelton, M. J. (2006). Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects. Antimicrob. Agents Chemother. 50: 3157-3159 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»